Epidarex Capital Leads Initial Investment in International Diabetes Start Up
In All, PortfolioGlasgow, United Kingdom, November 4th 2015 – Caldan Therapeutics Ltd (Caldan) has announced a £4.45 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Eli Lilly and Company is one of numerous limited partners in the fund….